作者
Lauren E Abrey, Tracy T Batchelor, Andrés JM Ferreri, Mary Gospodarowicz, Elisa J Pulczynski, Emanuele Zucca, Justine R Smith, Agnieszka Korfel, Carole Soussain, Lisa M DeAngelis, Edward A Neuwelt, Brian Patrick O'Neill, Eckhard Thiel, Tamara Shenkier, Fransesc Graus, Martin van den Bent, John F Seymour, Philip Poortmans, James O Armitage, Franco Cavalli
发表日期
2005/8/1
期刊
Journal of clinical oncology
卷号
23
期号
22
页码范围
5034-5043
出版商
American Society of Clinical Oncology
简介
Standardized guidelines for the baseline evaluation and response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparability among clinical trials for newly diagnosed patients. The relative rarity of this tumor precludes rapid completion of large-scale phase III trials and, therefore, our reliance on the results of well-designed phase II trials is critical. To formulate this recommendation, an international group of experts representing hematologic oncology, medical oncology, neuro-oncology, neurology, radiation oncology, neurosurgery, and ophthalmology met to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy. The response guidelines were based on the results of neuroimaging, corticosteroid use, ophthalmologic examination, and CSF cytology. A critical issue that …
引用总数
20052006200720082009201020112012201320142015201620172018201920202021202220232024420282532223536484239596548526384797143
学术搜索中的文章